Treatment With Elotuzumab in Combination With Dexamethasone Achieves a Complete Remission in a Previously Treated Patient With Multiple Myeloma: A Case Report

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e801-e804. doi: 10.1016/j.clml.2020.06.001. Epub 2020 Jun 7.

Authors

Sydney Meyers¹, Chace Henning¹, Regina Swift¹, Benjamin Eades¹, Tanya M Spektor², James R Berenson³

Affiliations

¹ James R. Berenson, MD, Inc, West Hollywood, CA.
² Oncotherapeutics, West Hollywood, CA.
³ James R. Berenson, MD, Inc, West Hollywood, CA; Oncotherapeutics, West Hollywood, CA; Institute for Myeloma and Bone Cancer Research, West Hollywood, CA. Electronic address: jberenson@imbcr.org.

PMID: 32682685
DOI: 10.1016/j.clml.2020.06.001

No abstract available

Keywords: B-cell malignancies; Humanized IgG1 monoclonal antibody; Immunomodulatory drugs; Plasma cell disorders; SLAMF7.

Publication types

Case Reports

MeSH terms

Aged, 80 and over
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use*
Dexamethasone / pharmacology
Dexamethasone / therapeutic use*
Humans
Male
Multiple Myeloma / drug therapy*
Remission Induction

Substances

Antibodies, Monoclonal, Humanized
elotuzumab
Dexamethasone